Last updated: November 5, 2026
Letermovir, marketed by Merck as Prevymis, is a CMV prophylaxis product with approximately $1 billion in annual sales and expanding use in transplant medicine. Its commercial position is supported by a differentiated mechanism, lower myelotoxicity than valganciclovir, and a 2023 FDA expansion into adult kidney-transplant recipients. The principal risks are concentration in transplant centers, competition from low-cost generic antivirals, payer pressure, and eventual erosion from patent and regulatory exclusivity loss.
How large is the letermovir market?
Letermovir addresses prophylaxis against clinically significant cytomegalovirus, or CMV, infection in high-risk transplant patients.
The FDA-approved uses are:
- CMV prophylaxis in adult and pediatric patients at least 12 years old and weighing at least 35 kilograms who received an allogeneic hematopoietic stem-cell transplant, or HSCT.
- CMV prophylaxis in adult kidney-transplant recipients at high risk, defined as donor-positive and recipient-negative CMV serostatus, through 200 days after transplantation.
The commercial market has two distinct segments:
| Segment |
Primary need |
Main competing therapy |
Commercial profile |
| Allogeneic HSCT |
Prevent CMV infection and disease during immune recovery |
Valganciclovir is limited by marrow toxicity; preemptive monitoring is common |
Higher medical value and specialist adoption |
| High-risk kidney transplant |
Long-course prophylaxis through post-transplant day 200 |
Valganciclovir |
Large expansion opportunity, but greater price sensitivity |
Merck’s commercial case is strongest where clinicians prioritize avoidance of neutropenia, anemia, thrombocytopenia, and treatment interruptions. Letermovir does not replace every CMV-management strategy. Some centers continue to use viral-load surveillance and preemptive therapy, particularly where formulary restrictions limit prophylactic use.
What are Prevymis sales and financial trends?
Prevymis has become a material Merck product, although it remains small relative to Keytruda and Merck’s broader oncology portfolio.
| Fiscal year |
Prevymis sales |
Year-over-year change |
Merck total sales |
Prevymis as share of Merck sales |
| 2021 |
Approximately $698 million |
Approximately 17% |
Approximately $57.7 billion |
1.2% |
| 2022 |
Approximately $819 million |
Approximately 17% |
Approximately $59.3 billion |
1.4% |
| 2023 |
Approximately $1.0 billion |
Approximately 23% |
Approximately $60.1 billion |
Approximately 1.7% |
Source: Merck annual reports for fiscal years 2021-2023.
The sales trajectory indicates three commercial drivers:
- Continued penetration in allogeneic HSCT.
- Increased recognition of letermovir’s tolerability advantages.
- The kidney-transplant indication approved in 2023.
The kidney-transplant expansion provides the clearest route to continued growth. The population is larger than the allogeneic HSCT population, and prophylaxis extends for approximately 200 days. The offset is that kidney-transplant patients are managed in a more cost-sensitive environment, with generic valganciclovir already established.
Prevymis sales of approximately $1 billion represent less than 2% of Merck’s consolidated revenue. The product is therefore commercially important as a growth asset but does not create the same company-wide concentration risk as Keytruda.
When did the FDA approve letermovir?
The FDA approved Prevymis on November 8, 2017, for CMV prophylaxis in adult CMV-seropositive recipients of an allogeneic HSCT. The approval was based principally on a randomized clinical trial showing lower rates of clinically significant CMV infection compared with placebo.
The FDA later approved letermovir for high-risk adult kidney-transplant recipients on June 5, 2023. The approval followed a phase 3 study in which letermovir was noninferior to valganciclovir for CMV disease prevention through approximately one year after transplantation.
Important regulatory milestones include:
| Date |
Milestone |
| November 8, 2017 |
Initial FDA approval for adult allogeneic HSCT recipients |
| 2018 |
European authorization for CMV prophylaxis in adult CMV-seropositive allogeneic HSCT recipients |
| 2023 |
FDA approval for high-risk adult kidney-transplant recipients |
| 2023 |
Label expansion and broader use of the oral and intravenous formulations |
The kidney-transplant approval materially improves the product’s addressable market. It also changes the competitive benchmark from placebo or preemptive therapy to valganciclovir.
How does letermovir compare with valganciclovir and maribavir?
Letermovir has a different clinical and commercial position from other CMV drugs.
| Drug |
Primary role |
Key advantage |
Key limitation |
| Letermovir |
CMV prophylaxis |
Lower marrow toxicity and no viral DNA polymerase inhibition |
High cost and drug-interaction management |
| Valganciclovir |
Prophylaxis and treatment |
Generic availability, broad clinical familiarity |
Myelosuppression and renal dosing requirements |
| Ganciclovir |
Treatment and preemptive therapy |
Established intravenous option |
Myelotoxicity and hospital-based administration |
| Maribavir |
Refractory or resistant CMV treatment |
Oral treatment option with a distinct mechanism |
Not a direct prophylaxis substitute |
Letermovir inhibits the CMV terminase complex, primarily through the UL56 component. Its mechanism differs from valganciclovir and ganciclovir, which inhibit viral DNA polymerase after intracellular activation. This difference supports use in patients where marrow suppression or prior antiviral exposure is a concern.
The main clinical advantage is reduced hematologic toxicity. The main commercial disadvantage is price. Generic valganciclovir creates a substantial reimbursement barrier, particularly in kidney transplantation.
Drug interactions also affect prescribing. Letermovir can interact with tacrolimus, cyclosporine, sirolimus, and certain statins through CYP3A and transporter pathways. Transplant programs can manage these interactions, but monitoring adds operational complexity.
What patents protect letermovir and Prevymis?
The letermovir patent estate includes compound, formulation, pharmaceutical-composition, and method-of-use protection. The relevant rights are held primarily by Merck entities following the company’s license and development agreement with AiCuris.
The original composition-of-matter protection dates from early letermovir development and has reached or approached the end of its ordinary U.S. patent term. Later patents and continuation filings may protect formulations, dosing regimens, crystalline forms, manufacturing processes, and transplant-specific uses.
| Patent category |
Commercial purpose |
Expected risk profile |
| Compound patents |
Protect letermovir’s chemical structure |
Earliest major expiry pressure |
| Formulation patents |
Protect oral tablets, granules, or intravenous compositions |
Can delay simple substitution if claims are enforceable |
| Method-of-use patents |
Protect CMV prophylaxis in transplant populations |
Relevant to skinny-label and induced-infringement disputes |
| Manufacturing patents |
Protect synthesis, purification, or solid-state processing |
Can raise entry costs but rarely blocks all generic development |
| Regulatory exclusivity |
Prevent certain FDA approvals for a defined period |
Time-limited and separate from patent rights |
Publicly identified U.S. patents associated with letermovir include U.S. Patent No. 7,601,820 and later patent families covering formulations and additional product attributes. Patent term and Orange Book status must be assessed by patent family, terminal disclaimers, pediatric extensions, and the specific claim scope.
The original five-year new chemical entity exclusivity period from the 2017 approval ended in 2022. That exclusivity period did not eliminate later patent protection. Any generic applicant seeking approval before relevant listed patent expiry would generally need to address the patents through a Paragraph IV certification or wait for expiry.
What is the Orange Book status of Prevymis?
Prevymis is an FDA-approved small-molecule drug listed in the Orange Book. Orange Book relevance depends on:
- The patents listed for the tablet and intravenous products.
- Whether the listed patent claims cover the active ingredient, formulation, or use.
- The expiration dates reported by the FDA.
- The use codes associated with approved CMV-prophylaxis indications.
- Any Paragraph IV certifications filed by abbreviated new drug application applicants.
A generic applicant can pursue several strategies:
- File a Paragraph III certification and wait for patent expiry.
- File a Paragraph IV certification challenging listed patents.
- Use a section viii statement and omit a patented indication from the label.
- Develop a product that avoids formulation or manufacturing claims.
The kidney-transplant indication creates a potential skinny-label issue. If a generic applicant omits the kidney-transplant use but retains an unpatented HSCT use, Merck could still argue induced infringement if marketing materials or clinical practice predictably encourage the omitted use. The strength of that argument would depend on claim language, prescribing patterns, and the final generic label.
Are there Paragraph IV challenges or letermovir patent lawsuits?
No major, widely reported U.S. Paragraph IV litigation has established a definitive generic launch date for Prevymis through the public record cited here. The absence of prominent litigation does not mean that generic development is absent. It may reflect the timing of ANDA filings, confidential settlements, patent-family complexity, or limited commercial incentives before the largest listed patents expire.
A meaningful litigation assessment should separate:
- Challenges to composition patents.
- Challenges to formulation claims.
- Challenges to transplant-specific method-of-use claims.
- Contractual settlements between Merck and ANDA applicants.
- Patent litigation involving process patents that may not appear in the Orange Book.
The most important commercial question is whether a generic can enter with an acceptable product that avoids late-expiring formulation or use claims. The answer is likely to differ between oral tablets and intravenous letermovir.
What licensing deal created Prevymis?
Merck obtained rights to letermovir from AiCuris, the German anti-infective company that discovered and developed the compound. The collaboration was announced in 2012 and provided Merck with global development and commercialization rights.
The transaction included an upfront payment and potential development, regulatory, and commercial milestone payments, together with royalties or other economic participation for AiCuris. Merck assumed the principal development and commercialization responsibilities that led to the Prevymis approval.
The deal reduced Merck’s discovery risk while giving AiCuris access to Merck’s global transplant and infectious-disease infrastructure. It also means that the economic value of Prevymis is divided between product revenue retained by Merck and contractual obligations to the originator.
How strong is the letermovir patent estate?
The estate is commercially meaningful but less durable than a portfolio anchored by a recently approved compound patent.
Strengths include:
- A differentiated chemical entity with specialized transplant use.
- Multiple product forms, including oral and intravenous administration.
- A clinically valuable prophylaxis indication.
- Potential method-of-use protection for high-risk transplant patients.
- Manufacturing complexity associated with high-purity active pharmaceutical ingredient and formulation control.
Weaknesses include:
- The age of the original compound patent family.
- Availability of generic valganciclovir.
- The ability of generic companies to design around individual formulation claims.
- The difficulty of using method-of-use patents to control off-label prescribing.
- Limited value of patent protection against preemptive CMV monitoring where physicians do not prescribe letermovir.
The estate is therefore stronger as a commercial barrier than as an absolute barrier to generic development. Market exclusivity will depend on the combined effect of patents, regulatory review timing, reimbursement, and transplant-center switching behavior.
What generic entry risks exist for letermovir?
The most likely launch scenarios are:
Scenario 1: No near-term generic entry
Merck retains substantial sales through continued patent protection, delayed ANDA review, or lack of an approved generic product. This scenario supports continued revenue growth from the kidney-transplant indication.
Scenario 2: Limited oral generic entry
A generic tablet launches after resolving or avoiding selected patents. Merck retains some share through brand contracting, intravenous supply, physician preference, and the clinical value of established dosing protocols.
Scenario 3: Broad generic substitution
An approved generic product covers the principal tablet indication and receives favorable payer placement. Price erosion accelerates, particularly in kidney transplantation, where valganciclovir already sets a low-cost benchmark.
Scenario 4: Indication-specific entry
A generic launches with an HSCT-only label or another limited indication. This would reduce immediate erosion but leave litigation risk around use-code scope and induced infringement.
The economic impact will depend more on the first substitutable generic than on the number of eventual entrants. Transplant drugs often have concentrated prescribing through hospitals and specialty pharmacies, which can accelerate formulary-driven switching once a generic is available.
What geographic markets matter for letermovir?
The United States is the largest commercial market because of higher reimbursement and Merck’s established transplant infrastructure. Europe provides a second major market, but pricing is constrained by national health systems and reference-pricing mechanisms.
Japan and other developed transplant markets contribute incremental revenue. Emerging markets are less attractive because:
- Transplant volumes are lower.
- Generic valganciclovir is widely available.
- CMV monitoring and preemptive treatment may be preferred.
- Premium prophylaxis pricing is difficult to sustain.
The highest-value markets are those with high allogeneic HSCT volumes, large kidney-transplant programs, and reimbursement systems that recognize reduced hospitalization and marrow-toxicity costs.
Key Takeaways
- Letermovir, marketed as Prevymis, generated approximately $1 billion in Merck sales in 2023.
- Sales grew approximately 23% in 2023, supported by transplant-center adoption and the FDA kidney-transplant expansion.
- The 2023 kidney-transplant approval is the main remaining market-expansion driver.
- Valganciclovir is the principal commercial competitor because it is generic and inexpensive.
- Letermovir’s strongest clinical advantage is lower marrow toxicity.
- Its original five-year FDA new chemical entity exclusivity ended in 2022.
- Later patents covering formulations, uses, and manufacturing processes remain relevant to generic timing.
- The product’s patent estate is commercially significant but does not guarantee protection through the full life of the kidney-transplant opportunity.
- No definitive public generic launch date or major Paragraph IV litigation outcome is established in the cited record.
- Prevymis is material to Merck’s growth portfolio but represents less than 2% of consolidated company revenue.
FAQs
Is letermovir used to treat active CMV infection?
No. Letermovir is approved primarily for prophylaxis. Maribavir, ganciclovir, valganciclovir, and foscarnet occupy more important roles in treatment of established or resistant CMV infection.
Why is letermovir more expensive than valganciclovir?
Letermovir is a newer branded product with differentiated clinical data and patent protection. Valganciclovir has generic competition and a longer-established treatment role.
Can letermovir be used in solid-organ transplant patients?
Yes. The FDA approved letermovir for CMV prophylaxis in high-risk adult kidney-transplant recipients. Use in other solid-organ transplant populations may depend on clinical evidence, institutional protocols, and labeling.
Does letermovir cause bone-marrow suppression?
It has substantially less marrow toxicity than valganciclovir and ganciclovir. Hematologic monitoring remains relevant because transplant recipients receive multiple drugs that can affect blood counts.
What is the main investment risk for Prevymis?
The principal risk is a combination of generic entry and slower-than-expected conversion of kidney-transplant patients from valganciclovir. Patent expiry alone does not determine the launch date, but it is the central long-term revenue risk.
References
- Merck & Co., Inc. (2022). 2021 annual report.
- Merck & Co., Inc. (2023). 2022 annual report.
- Merck & Co., Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2017). FDA approves new drug to prevent cytomegalovirus infection in transplant patients.
- U.S. Food and Drug Administration. (2023). FDA approves letermovir for prevention of CMV disease in adult kidney transplant recipients.
- U.S. Food and Drug Administration. (2024). Prevymis prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,601,820: Quinazoline derivatives.
- AiCuris Anti-infective Cures AG. (2012). Merck and AiCuris enter worldwide licensing agreement for letermovir.
